Skip to main content
. Author manuscript; available in PMC: 2015 Dec 5.
Published in final edited form as: Cell Rep. 2015 Nov 25;13(9):1789–1799. doi: 10.1016/j.celrep.2015.10.068

Figure 3. Vif screening identifies Vif-positions 19 and 22 to confer activity to A3G-125R.

Figure 3

(A) 66 patient-derived Vifs and LAI, NL4-3 and an inactive Vif were cloned into full-length NL4-3 and were tested in single cycle infectivity assays in the presence of WT A3G (top panel) or A3G-125R (bottom panel).

(B) The infectivity values in the presence of A3G-125R were divided by the infectivity values measured in the presence of WT A3G. The Vifs that can (in green) or cannot (in black) counteract A3G-125R are indicated.

(C) The frequency of the most abundant amino acid at each position of the Vifs able to counteract A3G-125R was divided by the amino acid frequency of the inactive Vifs using VESPA (Rose and Korber, 2000).

(D) Weblogo plot of amino acids 14–27 of the Vifs that fail to counteract A3G-125R (top) and that of the Vifs that efficiently counteract A3G-125R (bottom). See also Figure S1.

(E) Vif positions 19 and 22 are indicated in green on the Vif crystal structure. Both residues are in close proximity to Vif-14-17 (pink).